The investor letter highlights that Prolight has entered the year with several important milestones that further strengthen the position of our POC platform, Psyros™. Particularly encouraging is the progress in our ongoing funded collaboration with BRAINBox Solutions, where we have achieved highly positive results in an analytical evaluation of three biomarkers for Traumatic Brain Injury (TBI).
Read more about this exciting development in the attached document or on the company’s website:
https://prolightdx.com/en/mediaeng/investor-letters/